Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 12

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 8
Chunk 12
---
% if consultant is instrumental
in arranging a distribution arrangement not previously pursued by the Company, on terms acceptable to the Company, (c) 20% when such
Distribution Contract achieves $1 million in annual sales and (d) 15% when the consultant arranges the first Celebrity Golf Tournament
featuring Nugevia on terms and conditions acceptable to the Company.

The
significant inputs utilized to determine the grant date fair value of stock options issued during the nine month periods ended September
30, 2025 and 2024 were as follows:

 Schedule of Grant Date Fair Value of Stock Options Issued

    September
    30,  
    September
    30, 

    2025  
    2024 
  
    Dividend
    Yield 
     0% 
     0%
  
    Weighted
    average expected term (years) 
     5.38-6.00  
     5.75-6 
  
    Volatility 
     65.68-101.98% 
     97.3-105.8%
  
    Risk-free
    rate 
     3.86-4.18% 
     4.10%
  
    Weighted
    average exercise price 
    $0.97  
    $1.33 

    17

JUPITER
NEUROSCIENCES, INC.

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note
6 – Stockholders’ Equity, continued

A
summary of stock option activity for the nine months ended September 30, 2025 is presented below:

 Schedule of Stock Option Activity

    Number
    of Options  
    Weighted
    Average Exercise Price  
    Weighted
    Average Contractual Term (Years)  
    Aggregate
    Intrinsic Value 
  
    Outstanding
    as of December 31, 2024 
     10,633,988  
     1.02  
     6.25  
    $102,921,147 
  
    Granted 
     1,092,105  
     1.16  

    Exercised 
     -  
     -  

    Forfeited 
     -  
     -  

    Outstanding
    as of September 30, 2025 
     11,726,093